Video Experimental Relacionado

Updated: Sep 24, 2025

Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay PCA in Living Cells

Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay PCA in Living Cells

Published on: March 3, 2015

Descubrimiento sistemático de las interacciones neoproteína-proteína dirigidas por mutación en el cáncer

Xiulei Mo¹, Qiankun Niu², Andrey A Ivanov³

¹Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

|May 5, 2022

Resumen

Las mutaciones del cáncer pueden crear nuevas interacciones de proteínas, impulsando el crecimiento del tumor. Nuestro estudio identifica estas nuevas interacciones, revelando nuevos objetivos terapéuticos potenciales para la medicina de precisión.

Área de la Ciencia:

En el campo de la oncología
Biología molecular
La genómica

Sus antecedentes:

La secuenciación genómica revela mutaciones que conducen al cáncer.
Algunas mutaciones causan actividad neomorfa, alterando la función de la proteína.
La actividad neomorfa puede conducir a nuevas interacciones proteína-proteína (neoPPIs).

Objetivo del estudio:

Identificar las variantes prevalecientes de los neoIPP utilizando una plataforma de cribado de alto rendimiento.
Para entender cómo las mutaciones del cáncer crean nuevas interacciones de proteínas.
Para explorar estrategias terapéuticas basadas en estos neoPPIs.

Principales métodos:

Desarrolló una plataforma cuantitativa de cribado diferencial de alto rendimiento (qHT-dS).
Biosensores BRET sensibles acoplados con coexpresión miniaturizada en el cribado de ultra alto rendimiento (uHTS).
Interacciones monitoreadas de proteínas de tipo salvaje y mutantes con proteínas asociadas al cáncer en células vivas.

Principales resultados:

Se examinaron 17.792 interacciones, generando más de 2 millones de puntos de datos.
Se identificó un panorama de eventos de ganancia de interacción vinculados a mutaciones oncogénicas y supresoras de tumores.
La mutación BRAF V600E descubierta media en KEAP1 neoPPI, creando una vulnerabilidad a los sustratos NQO1.

Conclusiones:

Las alteraciones genómicas del cáncer pueden generar neo-interacciones.
Estos neoPPIs ofrecen información sobre los enfoques terapéuticos dirigidos a las variantes.
La terapia combinada dirigida al eje BRAF V600E/KEAP1 presenta una estrategia potencial.

Palabras clave:

El Consejo de Ministros genómica del cáncer objetivo de cáncer mutaciones del controlador el interactoma neoPPI (en inglés)el oncogén Interacción proteína-proteína Biología de sistemas supresor de tumores

Más Videos Relacionados

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Videos de Conceptos Relacionados

Protein Networks

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer-Critical Genes I: Proto-oncogenes

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...